Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy

Zhongyi Dong; Haoyu Zhang; Feng Xue; Long Bai; Qianyu Guo; Guy Robinson; Aya Elalfy; Tao Liu; Muerzhate Aimaiti; Xiang Xia; Shuguang Zuo; Zizhen Zhang

doi:10.1186/s12916-026-04661-x

January 30, 2026BMC MedicineOpen Access

Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the enhancement of oncolytic virotherapy using a tri-specific T-cell engager.
Armed oncolytic adenovirus applied in preclinical models
Targeting of CD3ε, EpCaM, and 4-1BB
Evaluation of antitumor immune responses
Enhanced antitumor immunity observed with the tri-specific T-cell engager
Integration of costimulatory signals improved treatment efficacy
Potential for more effective cancer immunotherapy strategies indicated

Implication

Preclinical evaluation shows enhanced antitumor immunity in cancer, suggesting a more effective immunotherapy strategy.

Abstract

Oncolytic adenovirus armed with TriTE enhances antitumor immunity by integrating costimulatory signaling. Incorporating costimulatory molecules into oncolytic virotherapy may offer more effective cancer immunotherapy strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dong et al. (2026) studied this question.

synapsesocial.com/papers/6980ff08c1c9540dea811b00 https://doi.org/10.1186/s12916-026-04661-x

View Full Paper

Ask AI

Bookmark

Share

Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading